Factor VIII-von willebrand factor binding defects in autosomal recessive von willebrand disease type normandy and in mild hemophilia A

Acta Haematologica

Volumn 121, Issue 2-3, 2009, Pages 102-105

  Jacquemin, Marc ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Desmopressin; Factor VIII binding; Hemophilia A; Normandy; Von Willebrand disease type 2N

Indexed keywords

BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; VASOPRESSIN; VON WILLEBRAND FACTOR; ARGIPRESSIN[1 DEAMINO]; VON WILLEBRAND FACTOR NORMANDY;

AUTOSOMAL RECESSIVE DISORDER; DISEASE CLASSIFICATION; GENE INTERACTION; HEMOPHILIA A; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE; BINDING SITE; ENDOTHELIUM CELL; GENETICS; LUNG; METABOLIC CLEARANCE RATE; METABOLISM; POINT MUTATION; PROTEIN ANALYSIS; PROTEIN TERTIARY STRUCTURE; PROTEIN TRANSPORT; RECESSIVE GENE;

BINDING SITES; DEAMINO ARGININE VASOPRESSIN; ENDOTHELIAL CELLS; FACTOR VIII; GENES, RECESSIVE; HEMOPHILIA A; HUMANS; LUNG; METABOLIC CLEARANCE RATE; MUTATION, MISSENSE; POINT MUTATION; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 67649651890     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000214849     Document Type: Review

References (21)

1. Weiss HJ, Sussman II, Hoyer LW: Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977;60:390-404.
2. Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D: New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 7 4 : 1591-159 9.
3. Tuley EA, Gaucher C, Jorieux S, Worrall NK, Sadler JE, Mazurier C: Expression of von Willebrand factor 'Normandy': an autosomal mutation that mimics hemophilia A. Proc Natl Acad Sci USA 1991; 88: 6377-6381.
4. Leyte A, van Schijndel HB, Niehrs C, Huttner WB, Verbeet MP, Mertens K, van Mourik JA: Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 1991;266:740-746.
5. Gilles JG, Lavend'homme R, Peerlinck K, Jacquemin MG, Hoylaerts M, Jorieux S, Ma-zurier C, Vermylen J, Saint-Remy JM: Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes. Thromb Haemost 1999; 82: 40-45.
6. Jacquemin M, Lavend'homme R, Benhida A, Vanzieleghem B, d'Oiron R, Lavergne JM, Brackmann HH, Schwaab R, VandenDriessche T, Chuah MK, Hoylaerts M, Gilles JG, Peerlinck K, Vermylen J, Saint-Remy JM: A novel cause of mild/moderate haemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor. Blood 2000; 96:958-965.
7. Liu ML, Shen BW, Nakaya S, Pratt K P, Fujikawa K, Davie EW, Stoddard BL, Thompson AR: Hemophilic factor VIII C1- and C2-do-main missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood 2000; 96:979-987.
8. D'Oiron R, Lavergne JM, Lavend'homme R, Benhida A, Bordet JC, Negrier C, Peerlinck K, Vermylen J, Saint-Remy JM, Jacquemin M: Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development. Blood 2004; 103:155-157.
9. Cattaneo M, Simoni L, Gringeri A, Mannucci PM: Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor. Br J Haematol 1994;86:333- 337.
10. Haberichter SL, Shi Q, Montgomery RR: Regulated release of VWF and FVIII and the biologic implications. Pediatr Blood Cancer 2006;46:547-553.
11. Jacquemin M, Neyrinck A, Hermanns MI, Lavend'homme R, Rega F, Saint-Remy JM, Peerlinck K, Van Raemdonck D, Kirkpatrick CJ: FVIII production by human lung microvascular endothelial cells. Blood 2006;108: 515-517.
12. Jacquemin MG, Lavend'homme R, Saint-Remy J, Peerlinck K: Activation of human lung endothelial cells induces the release of a FVIII storage pool. J Thromb Haemost 2007; 5(suppl 2):P-M-026.
13. Kroner PA, Friedman KD, Fahs SA, Scott JP, Montgomery RR: Abnormal binding of factor V III is linked with the subst it ution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease. J Biol Chem 1991;266:19146-19149.
14. 53→Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor. Blood 1992;79:563-567.
15. Kroner PA, Foster PA, Fahs SA, Montgomery RR: The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor. Blood 1996;87: 1013-1021.
16. University of Sheffield: ISTH SSC VWF Database: http://www.vwf.group. shef.ac.uk/index.html
17. Gu J, Jorieux S, Lavergne JM, Ruan C, Mazurier C, Meyer D: A patient with type 2N von Willebrand disease is heterozygous for a new mutation: Gly22Glu. Demonstration of a defective expression of the second allele by the use of monoclonal antibodies. Blood 1997; 89:3263-3269.
18. Peerlinck K, Eikenboom JC, Ploos Van Amstel HK, Sangtawesin W, Arnout J, Reitsma PH, Vermylen J, Briët E: A patient with von Willebrand's disease characterized by a compound heterozygosity for a substitution of Arg854 by Gln in the putative factor-VIII-binding domain of von Willebrand factor (vWF) on one allele and very low levels of mRNA from the second vWF allele. Br J Haematol 1992; 80:358-363.
19. Mazurier C, Gaucher C, Jorieux S, Goudemand M: Biological effect of desmopressin in eight patients with type 2N ('Normandy') von Willebrand disease. Collaborative Group. Br J Haematol 1994;88:849-854.
20. Peerlinck K, Jacquemin MG, Arnout J, Hoylaerts MF, Gilles JG, Lavend'homme R, Johnson KM, Freson K, Scandella D, Saint-Remy JM, Vermylen J: Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 1999;93:2267-2273.
21. D'Oiron R, Lavergne JM, Peynet J, Jacquemin M, Oldenburg J, Guillet B, Rafowicz A, Lavend'homme R, Peerlinck K, Lambert T, Brackmann H, Saint-Remy JM, Vermylen J, Schwaab R: Response to DDAVP in mild/ moderate hemophilia A patients according to the underlying factor VIII genotype. J Thromb Haemost 2003; 1(suppl 1):0C-214.